Common Side Effects and Their Frequency
Ezetimibe (Zetia) typically causes side effects in 2-4% of patients overall, based on clinical trials. The most frequent include upper respiratory tract infections (4.3%), diarrhea (2.5%), and joint pain (2.5-3%). Serious reactions like liver enzyme elevations occur in under 1%.[1]
Vascepa (icosapent ethyl) shows side effects in about 20-25% of users in major trials like REDUCE-IT. Common ones are musculoskeletal pain (12-14%), peripheral edema (10-12%), and constipation (5%). Atrial fibrillation or bleeding events rise modestly (e.g., 5% vs. 4% placebo for bleeding).[2]
Side Effects When Taking Ezetimibe and Vascepa Together
No large dedicated trials test this exact combo, but data from combo studies with statins (e.g., IMPROVE-IT trial for ezetimibe + simvastatin) suggest additive risks without major interactions. Expect overlapping issues like muscle pain (3-5% combined risk) or gastrointestinal upset (5-10%). Vascepa's omega-3 effects may slightly increase bleeding risk if paired with ezetimibe's rare liver impacts, but this affects <2%.[1][3]
Real-world reports from patient registries indicate mild effects in most (under 10% discontinue), with GI complaints leading complaints.[4]
Factors Affecting Side Effect Likelihood
Dose matters: Standard ezetimibe (10 mg daily) has lower rates than higher doses; Vascepa (4 g daily) doubles some risks vs. 2 g. Pre-existing conditions raise odds—e.g., diabetes patients on Vascepa see 1.5x more palpitations.[2]
Duration: Side effects peak in first 1-3 months, often resolving; long-term use (years) keeps rates stable at 5-15% for either drug.[1][2]
Monitoring and When to Worry
Doctors recommend baseline liver tests for ezetimibe and bleeding checks for Vascepa. Contact a provider if muscle weakness, unexplained bleeding, or severe diarrhea hits— these occur in 1-3% but need prompt evaluation. Most users (75-90%) report no or minimal issues.[3][4]
[1]: https://www.accessdata.fda.gov/drugsatfdadocs/label/2012/021445s033lbl.pdf (Ezetimibe label)
[2]: https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202057s024lbl.pdf (Vascepa label)
[3]: IMPROVE-IT trial, NEJM 2015; https://www.nejm.org/doi/full/10.1056/NEJMoa1410489
[4]: FDA Adverse Event Reporting System (FAERS) summary for ezetimibe/icosapent ethyl combos